O
OKYO Pharma Limited
Biotechnology: Biological Products (No Diagnostic Substances) company
Key Metrics of OKYO Pharma Limited
Market cap$77.1MOKYO · $1.47
Competitors10identified
About OKYO Pharma Limited
Sectors
Company details
- Founded
- 2022
- Listed
- Nasdaq: OKYO (since 2022)
Operational Areas of OKYO Pharma Limited
Pharmaceuticals & Healthcare›Biotechnology & Vaccines
Company summary
Legal nameOKYO Pharma Limited
TickerOKYO
ExchangeNasdaq
CountryGuernsey
SEC CIK0001849296
Listed since2022
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
SectorPharmaceuticals & Healthcare · Biotechnology & Vaccines
Website—
US market & SEC filings
OKYO · Nasdaq · SEC CIK 0001849296
Last price · 24 Oct 2026
$1.47
−4.55%
Market cap$77.1M
P/E—
Volume72,483
SectorHealth CareBiotechnology: Biological Products (No Diagnostic Substances)
Country · IPOGuernseyListed 2022
OKYO share price
Annual results (SEC EDGAR)
No annual results in SEC XBRL data for this company yet.
Vendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered office—
GSTIN—
Email—
Website—
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of OKYO Pharma Limited
Competitors10identified
Countries2most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Part of Vertex Pharmaceuticals. | vrtx.com | 1991 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | gsk.com | 2022 | United Kingdom | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | modernatx.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bd.com | — | United States | |
| Part of Illumina. | illumina.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | guardanthealth.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | revvity.com | — | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | exelixis.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | neurocrine.com | 1996 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | biomarin.com | 1999 | United States |
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.